GE closes $860m Vital Signs takeover
This article was originally published in Clinica
UK-based medtech giant GE Healthcare has finalised its acquisition of medical device manufacturer Vital Signs in an $860m takeover. The deal, which was first announced in July (see Clinica No 1317, p 2), provides GE with Vital Signs’ portfolio of single-patient use products used in anaesthesia, respiratory, sleep therapy and emergency medicine procedures. According to GE, this acquisition will allow it to offer its customers “significant cost advantages and improved patient care features, including reducing the likelihood of transmitting infections from one patient to another”. Vital Signs (Totowa, New Jersey) will be incorporated into GE’s Clinical Systems business.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals